MDT-AP-0715
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 69
- os_event
- false
- age_years
- 5.16
- sex
- F
- new_clusters
- C3
- umap1_2d
- 6.107908382
- umap2_2d
- 3.232092419
- umap1_3d
- 2.864713808
- umap2_3d
- -2.782274195
- umap3_3d
- -2.490192676
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.350
- DNA_REPAIR+0.270
- MITOTIC_SPINDLE+0.270
- E2F_TARGETS+0.230
- SPERMATOGENESIS+0.210
- G2M_CHECKPOINT+0.200
- WNT_BETA_CATENIN_SIGNALING+0.110
- APICAL_JUNCTION+0.060
- PANCREAS_BETA_CELLS+0.040
- FATTY_ACID_METABOLISM+0.030
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.520
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- TNFA_SIGNALING_VIA_NFKB-0.490
- ALLOGRAFT_REJECTION-0.470
- KRAS_SIGNALING_UP-0.460
- APOPTOSIS-0.440
- COMPLEMENT-0.440
- ANDROGEN_RESPONSE-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518343 | — | E | 0.925 |
| 2 | BS_A87NPZAP | medulloblastoma | — | 0.920 |
| 3 | BS_D0RDN4K5 | Embryonal tumors | — | 0.916 |
| 4 | BS_4W68NV3M | medulloblastoma | — | 0.904 |
| 5 | SRR2016967 | — | — | 0.902 |
| 6 | BS_V9HVBBDW | medulloblastoma | — | 0.901 |
| 7 | MDT-AP-0350 | Med | Medulloblastoma | 0.901 |
| 8 | TCGA-LQ-A4E4-01A-11R-A266-07 | — | B | 0.900 |
| 9 | MDT-AP-1345 | Med | Medulloblastoma | 0.899 |
| 10 | C3N-03886 | — | cohortMD1 | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |